Table 2.
Case mix, outcome and activity for major subgroups of dermatological admissions
| Infective conditions | Dermatological malignancies | Acute skin failure | |
| Admissions, n (% of all admissions) | 1,926 (0.40) | 191 (0.04) | 199 (0.04) |
| Age, mean (SD) | 57.6 (16.5) | 65.1 (15.0) | 51.7 (20.8) |
| Male, n (%) | 1,009 (52.4) | 112 (58.6) | 90 (45.2) |
| Surgical status, n (%): | |||
| Non-surgical | 1,016 (52.8) | 38 (19.9) | 170 (85.4) |
| Elective | 172 (8.9) | 138 (72.3) | 16 (8.0) |
| Emergency | 737 (38.3) | 15 (7.9) | 13 (6.5) |
| Past medical history*, n (%): | |||
| Steroid treatment | 65 (3.4) | 3 (1.6) | 12 (6.1) |
| Chemotherapy | 43 (2.3) | 8 (4.2) | 13 (6.6) |
| Metastatic disease | 17 (0.9) | 25 (13.2) | 0 (0.0) |
| Chronic renal replacement therapy | 37 (1.9) | 1 (0.5) | 5 (2.5) |
| Severe respiratory disease | 32 (1.7) | 1 (0.5) | 3 (1.5) |
| Very severe cardiovascular disease | 26 (1.4) | 3 (1.6) | 3 (1.5) |
| Radiotherapy | 15 (0.8) | 11 (5.8) | 1 (0.5) |
| Lymphoma | 19 (1.0) | 1 (0.5) | 6 (3.0) |
| Acute myelogenous/lymphocytic leukaemia or multiply myeloma | 11 (0.6) | 0 (0.0) | 3 (1.5) |
| Portal hypertension | 12 (0.6) | 0 (0.0) | 1 (0.5) |
| Biopsy proven cirrhosis | 12 (0.6) | 0 (0.0) | 0 (0.0) |
| Chronic myelogenous/lymphocytic leukaemia | 8 (0.4) | 1 (0.5) | 1 (0.5) |
| Home ventilation | 8 (0.4) | 1 (0.5) | 0 (0.0) |
| Congenital immunohumoral or cellular immune deficiency state | 5 (0.3) | 0 (0.0) | 1 (0.5) |
| Hepatic encephalopathy | 5 (0.3) | 0 (0.0) | 0 (0.0) |
| AIDS | 2 (0.1) | 0 (0.0) | 0 (0.0) |
| APACHE II score, mean (SD) | 19.1 (7.5) | 14.5 (5.3) | 18.1 (7.0) |
| ICNARC model: | |||
| Physiology score, mean (SD) | 22.7 (10.4) | 12.1 (6.7) | 21.2 (10.6) |
| Predicted mortality, median (IQR) | 37.6 (16.7–64.5) | 10.1 (6.2–19.2) | 32.7 (12.3–62.7) |
| ICU length of stay (days), median (IQR): | |||
| ICU survivor | 4.1 (1.7–10.0) | 1.0 (0.8–2.0) | 4.7 (1.9–14.8) |
| ICU non-survivor | 1.9 (0.7–5.8) | 1.0 (0.3–4.0) | 4.7 (2.0–10.0) |
| Transfer to another ICU | 4.0 (0.9–9.6) | - | 3.5 (0.7–11.6) |
| Total acute hospital length of stay (days), median (IQR): | |||
| Hospital survivor | 39 (22–66) | 17 (8–28) | 34 (16–75) |
| Hospital non-survivor | 9 (3–29) | 6 (3–22) | 15 (7–31) |
| ICU bed days (% of total bed days) | 13,808 (0.60) | 391 (0.02) | 1,923 (0.08) |
| Transfer to another ICU, n (%) | 72 (3.7) | 0 (0.0) | 12 (6.0) |
| ICU mortality, n (%) | 553 (28.7) | 12 (6.3) | 70 (35.2) |
| Ultimate hospital mortality, n (%) | 757 (41.5) | 24 (13.0) | 90 (46.6) |
Values are n (%), mean (SD) or median (IQR), as indicated. *Percentage of admissions with evidence to assess past medical history. APACHE, Acute Physiology And Chronic Health Evaluation; ICNARC, Intensive Care National Audit & Research Centre; ICU, intensive care unit; IQR, interquartile range; SD, standard deviation.